氘可来昔替尼片 | China Drugs ListDeucravacitinib tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- Bristol-Myers SquibbPharma EEIGBristol-Myers Squibb Pharma EEIG
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 皮肤科Dermatology
- 公开来源记录的适应症
- （1）适合系统治疗或光疗的中重度斑块状银屑病成人患者;（2）既往改善病情抗风湿药(DMARD)应答不佳或不耐受的活动性银屑病关节炎成人患者。1. Adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 2. Adults with active psoriatic arthritis who responded inadequately to, or could not tolerate, a disease-modifying antirheumatic drug (DMARD).
- 适应症来源与口径
- 来源日期： 2026-06-15. 新增适应症可能由较新的公告或申报资料支持，而非旧版完整说明书；请查看适应症来源。Source date(s): 2026-06-15. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
- 说明书信息局限
- 已找到官方药品说明书链接；尚未核实文件正文。Official prescribing-information link located; the document body has not yet been verified.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 日本, 英国: 已取得当地获批／上市公告及官方价格来源。每条价格记录注明适应症与日期；未全面核查其他市场。Japan, United Kingdom: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限适合系统治疗或光疗的成年中重度斑块状银屑病患者。Limited to adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- 医保期限
- 2025-01-01 至 2026-12-312025-01-01 to 2026-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.